Methods
In a retrospective, case-control study, the time course of some endothelial (MCP-1, sVCAM-1) and platelet activation markers (sPLA2, sGPV, sP-sel) was examined in 62 HIV-infected patients, before starting HAART and after 6-12 months of therapy with either Abacavir (n=31) or Tenofovir (n=31). Data were compared with those from 20 untreated HIV-infected patients at diagnosis and after 6 months and 10 healthy matched controls.
Results
Soluble P-selectin (sP-sel), sPLA2, soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) were significantly higher in HIV-infected patients than in healthy controls. During 6-12 months of follow-up, we found no significant differences between abacavir and tenofovirtreatment for endothelial markers, while sPLA2 (2113.6 ±39.5 vs 2742.5±29.7pg/ml, p<0.05) and sPsel (524±53.2 vs 713.47±20.3ng/ml, p<0.05) increased significantly in the abacavir group as compared with the tenofovir-treated group. sGPV, the platelet glycoprotein V major fragment released upon thrombin cleavage, was increased after 6-12 months as compared to baseline in both treatment groups (Abacavir: 89.7±13.7 vs 118.64±15.3 ng/ml Tenofovir: 133.5±10.7 vs 157.36±11.2, p<0.05). In naïve patients, not treated with HAART, significantly increased plasma markers of endothelial dysfunction sPsel and sPLA2 were confirmed at diagnosis, as compared with healthy controls, with no changes upon follow-up.
Conclusions
Our results confirm that chronic HIV infection induces endothelial dysfunction but indicate that a short-term treatment with abacavir enhances also some parameters of platelet activation, suggesting a role of platelets too in the increased incidence of ischemic cardiovascular events in HIV-infected patients treated with abacavir.
